
Opium (Opioid) Addiction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Opium (Opioid) Addiction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Opium (Opioid) Addiction - Drugs In Development, 2022, provides an overview of the Opium (Opioid) Addiction (Central Nervous System) pipeline landscape.
Opioid Addiction develops after using opioids regularly for a period of time. Prolonged use of opiates can lead to nerve damage within the brain that causes cells to stop producing endogenous opiates (natural painkillers known as endorphins). This can lead to an inability for the body to stop pain because there are no endorphins to mask the pain initially. The degeneration of the nerve cells that reduce pain can lead to a physical dependence on opiates as an external supply source. Signs and symptoms include increased general anxiety, euphoria, psychosis, depression, high blood pressure, decreased appetite, physical agitation, difficulty sleeping and pain in the bones. The predisposing factors include age, a personal history of substance abuse, and family history of substance abuse, cigarette dependency and psychologic stress.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Opium (Opioid) Addiction - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Opium (Opioid) Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Opium (Opioid) Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Opium (Opioid) Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 9, 15, 1, 36, 9 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 2 and 5 molecules, respectively.
Opium (Opioid) Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Opium (Opioid) Addiction - Drugs In Development, 2022, provides an overview of the Opium (Opioid) Addiction (Central Nervous System) pipeline landscape.
Opioid Addiction develops after using opioids regularly for a period of time. Prolonged use of opiates can lead to nerve damage within the brain that causes cells to stop producing endogenous opiates (natural painkillers known as endorphins). This can lead to an inability for the body to stop pain because there are no endorphins to mask the pain initially. The degeneration of the nerve cells that reduce pain can lead to a physical dependence on opiates as an external supply source. Signs and symptoms include increased general anxiety, euphoria, psychosis, depression, high blood pressure, decreased appetite, physical agitation, difficulty sleeping and pain in the bones. The predisposing factors include age, a personal history of substance abuse, and family history of substance abuse, cigarette dependency and psychologic stress.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Opium (Opioid) Addiction - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Opium (Opioid) Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Opium (Opioid) Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Opium (Opioid) Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 9, 15, 1, 36, 9 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 2 and 5 molecules, respectively.
Opium (Opioid) Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Opium (Opioid) Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Opium (Opioid) Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Opium (Opioid) Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Opium (Opioid) Addiction (Central Nervous System)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Opium (Opioid) Addiction (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Opium (Opioid) Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
153 Pages
- Introduction
- Global Markets Direct Report Coverage
- Opium (Opioid) Addiction – Overview
- Opium (Opioid) Addiction – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Opium (Opioid) Addiction – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Opium (Opioid) Addiction – Companies Involved in Therapeutics Development
- Adial Pharmaceuticals Inc
- Alar Pharmaceuticals Inc
- Amygdala Neurosciences Inc
- Ananda Scientific Inc
- Antheia Inc
- Aoxing Pharmaceutical Company Inc
- Aphios Corp
- Aquilus Pharmaceuticals Inc
- Atai Life Sciences NV
- Benuvia Therapeutics Inc
- BioCorRx Inc
- BioXcel Therapeutics Inc
- Bridge Therapeutics Inc
- Bright Minds Biosciences Inc
- Camurus AB
- Ceruvia Lifesciences LLC
- Cessation Therapeutics LLC
- Copernicus Therapeutics Inc
- Creative Bio-Peptides Inc
- Delpor Inc
- DemeRx Inc
- DMK Pharmaceuticals Inc
- Elysium Therapeutics Inc
- Emergent BioSolutions Inc
- Ensysce Biosciences Inc
- Eolas Therapeutics Inc
- Epiodyne Inc
- Ethismos Research Inc
- Exxel Pharma Inc
- Fab’entech SA
- Fannin Partners LLC
- Gilgamesh Pharmaceuticals Inc
- Hunan Saiao Pharmaceutical Co Ltd
- Indivior Plc
- Inimmune Corp
- Jazz Pharmaceuticals Plc
- Kinoxis Therapeutics Pty Ltd
- Lyndra Therapeutics Inc.
- Mayne Pharma Group Ltd
- Mebias Discovery LLC
- Mind Medicine MindMed Inc
- Nirsum Laboratories Inc
- Omeros Corp
- Opiant Pharmaceuticals Inc
- Orexo AB
- Orphomed Inc
- Osmotica Pharmaceutical Corp
- OYE Therapeutics Inc
- Palisades Therapeutics
- Phoenix PharmaLabs Inc
- Plumb Pharmaceuticals LLC
- Revive Therapeutics Ltd
- SafeRX Pharmaceuticals Inc
- Sen-Jam Pharmaceutical LLC
- Senzer Ltd
- Serina Therapeutics Inc
- Sparian Biosciences Inc
- Syntropharma Ltd
- Titan Pharmaceuticals Inc
- VDM Biochemicals Inc
- Vivreon Biosciences LLC
- Yichang Humanwell Pharmaceutical Co Ltd
- Zynerba Pharmaceuticals Inc
- Opium (Opioid) Addiction – Drug Profiles
- (buprenorphine + naloxone) – Drug Profile
- (buprenorphine + naloxone) – Drug Profile
- (buprenorphine hydrochloride + naloxone hydrochloride) – Drug Profile
- (cannabidiol + dronabinol) – Drug Profile
- (disulfiram + methadone hydrochloride) IR – Drug Profile
- (disulfiram + oxycodone hydrochloride) IR – Drug Profile
- ALA-1300 – Drug Profile
- amitifadine – Drug Profile
- ANS-6637 – Drug Profile
- Antibody for Drug Overdose, Opioid Addiction and Poisoning – Drug Profile
- APH-1501 – Drug Profile
- AQU-010 – Drug Profile
- arbaclofen ER – Drug Profile
- ATLX–0199 – Drug Profile
- BICX-101 SR – Drug Profile
- BICX-102 – Drug Profile
- BMB-101 – Drug Profile
- buprenorphine – Drug Profile
- buprenorphine ER – Drug Profile
- buprenorphine PR – Drug Profile
- buprenorphine SR – Drug Profile
- cannabidiol – Drug Profile
- dexmedetomidine – Drug Profile
- DPI-125 – Drug Profile
- Drug to Inhibit PDE4 for Opioid Addiction – Drug Profile
- EORA-101 – Drug Profile
- Gene Therapy for Opioid use Disorder – Drug Profile
- GM-1020 – Drug Profile
- GM-300X – Drug Profile
- hydrocodone IR – Drug Profile
- ibogaine – Drug Profile
- INDV-2000 – Drug Profile
- Kapanol – Drug Profile
- KNX-100 – Drug Profile
- KUR-101 – Drug Profile
- levomethadone ER – Drug Profile
- LSP-29166 – Drug Profile
- MEB-1170 – Drug Profile
- Monoclonal Antibody for Opioid Use Disorder – Drug Profile
- nalmefene – Drug Profile
- nalmefene SR – Drug Profile
- naltrexone – Drug Profile
- naltrexone ER – Drug Profile
- naltrexone hydrochloride – Drug Profile
- naltrexone LA – Drug Profile
- naltrexone SR – Drug Profile
- Noribogaine – Drug Profile
- NRS-033 – Drug Profile
- NRS-067 – Drug Profile
- NYPRG-101 – Drug Profile
- OMS-405 – Drug Profile
- OMS-527 – Drug Profile
- Ondansetron hydrochloride – Drug Profile
- Opioid Addiction – Drug Profile
- Opioid Vaccine Program – Drug Profile
- OPNT-006 – Drug Profile
- ORP-106 – Drug Profile
- OYE-001 – Drug Profile
- PF-26810 ER – Drug Profile
- PPL-103 – Drug Profile
- psilocybin For Opium (Opioid) Addiction – Drug Profile
- PT-150 – Drug Profile
- RAP-103 – Drug Profile
- SBS-226 – Drug Profile
- SER-227 – Drug Profile
- SJP-006 – Drug Profile
- SJP-007 – Drug Profile
- Small Molecule to Antagonize D3 Receptor for Opioid Addiction – Drug Profile
- Small Molecules to Antagonize Mu Receptor for Opioid Use Disorder – Drug Profile
- thienorphine hydrochloride – Drug Profile
- URB-937 – Drug Profile
- Vaccine 1 for Opioid Addiction – Drug Profile
- Vaccine for Opioid Addiction – Drug Profile
- Vaccine for Opioid Use Disorder – Drug Profile
- Vaccine for Opium Addiction – Drug Profile
- VDM-001 – Drug Profile
- VV-7063 – Drug Profile
- zolunicant hydrochloride – Drug Profile
- Opium (Opioid) Addiction – Dormant Projects
- Opium (Opioid) Addiction – Discontinued Products
- Opium (Opioid) Addiction – Product Development Milestones
- Featured News & Press Releases
- Apr 28, 2022: Delpor announces first subjects dosed in phase 1 clinical trial of once or twice-yearly naltrexone implant for opioid addiction
- Apr 27, 2022: BioCorRx begins recruitment for clinical trial of BICX104, an implantable naltrexone pellet for the treatment of opioid use disorder
- Apr 11, 2022: BioCorRx announces additional award of nearly $100,000 from NIDA for BICX104, its implantable naltrexone pellet for the treatment of opioid use disorder
- Mar 16, 2022: BioCorRx announces IRB approval to begin phase I clinical trial of BICX104, an implantable biodegradable Naltrexone Pellet for the treatment of opioid use disorder
- Feb 14, 2022: BioCorRx announces Orange County Research Center as clinical trial site for first-in-human clinical trial of BICX104
- Jan 24, 2022: Adial Pharmaceuticals receives notice of allowance on U.S. patent for the treatment for opioid use disorder using AD04
- Jan 12, 2022: Alar announces significant progress on developing long-acting buprenorphine injectable ALA-1000
- Jan 04, 2022: ANANDA Scientific announces FDA approval of the IND for the clinical trial on the treatment of Opioid Use Disorder (OUD)
- Jan 04, 2022: MindMed successfully completes phase 1 clinical trial of 18-MC
- Oct 19, 2021: ANANDA Scientific’s Liquid Structure cannabidiol (CBD) to be clinically evaluated for opioid use disorder
- Oct 07, 2021: BioCorRx files patent application with the Russian Patent Office (Rospatent) for Naltrexone Implant
- Sep 29, 2021: ANANDA Scientific and David Geffen School of Medicine UCLA announce clinical trial utilizing liquid structure cannabidiol (CBD) for the treatment of opioid use disorder (OUD)
- Sep 22, 2021: BioCorRx files patent application with USPTO for Naltrexone implant
- Sep 22, 2021: Bright Minds Biosciences provides scientific update
- Sep 21, 2021: DemeRx doses first subject in phase 1/2a study of DMX-1002 (Ibogaine) in opioid use disorder
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development for Opium (Opioid) Addiction, 2022
- Table 2: Number of Products under Development by Companies, 2022
- Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
- Table 4: Number of Products under Development by Companies, 2022 (Contd..2)
- Table 5: Number of Products under Development by Universities/Institutes, 2022
- Table 6: Products under Development by Companies, 2022
- Table 7: Products under Development by Companies, 2022 (Contd..1)
- Table 8: Products under Development by Companies, 2022 (Contd..2)
- Table 9: Products under Development by Companies, 2022 (Contd..3)
- Table 10: Products under Development by Universities/Institutes, 2022
- Table 11: Number of Products by Stage and Target, 2022
- Table 12: Number of Products by Stage and Target, 2022 (Contd..1)
- Table 13: Number of Products by Stage and Mechanism of Action, 2022
- Table 14: Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
- Table 15: Number of Products by Stage and Route of Administration, 2022
- Table 16: Number of Products by Stage and Molecule Type, 2022
- Table 17: Opium (Opioid) Addiction – Pipeline by Adial Pharmaceuticals Inc, 2022
- Table 18: Opium (Opioid) Addiction – Pipeline by Alar Pharmaceuticals Inc, 2022
- Table 19: Opium (Opioid) Addiction – Pipeline by Amygdala Neurosciences Inc, 2022
- Table 20: Opium (Opioid) Addiction – Pipeline by Ananda Scientific Inc, 2022
- Table 21: Opium (Opioid) Addiction – Pipeline by Antheia Inc, 2022
- Table 22: Opium (Opioid) Addiction – Pipeline by Aoxing Pharmaceutical Company Inc, 2022
- Table 23: Opium (Opioid) Addiction – Pipeline by Aphios Corp, 2022
- Table 24: Opium (Opioid) Addiction – Pipeline by Aquilus Pharmaceuticals Inc, 2022
- Table 25: Opium (Opioid) Addiction – Pipeline by Atai Life Sciences NV, 2022
- Table 26: Opium (Opioid) Addiction – Pipeline by Benuvia Therapeutics Inc, 2022
- Table 27: Opium (Opioid) Addiction – Pipeline by BioCorRx Inc, 2022
- Table 28: Opium (Opioid) Addiction – Pipeline by BioXcel Therapeutics Inc, 2022
- Table 29: Opium (Opioid) Addiction – Pipeline by Bridge Therapeutics Inc, 2022
- Table 30: Opium (Opioid) Addiction – Pipeline by Bright Minds Biosciences Inc, 2022
- Table 31: Opium (Opioid) Addiction – Pipeline by Camurus AB, 2022
- Table 32: Opium (Opioid) Addiction – Pipeline by Ceruvia Lifesciences LLC, 2022
- Table 33: Opium (Opioid) Addiction – Pipeline by Cessation Therapeutics LLC, 2022
- Table 34: Opium (Opioid) Addiction – Pipeline by Copernicus Therapeutics Inc, 2022
- Table 35: Opium (Opioid) Addiction – Pipeline by Creative Bio-Peptides Inc, 2022
- Table 36: Opium (Opioid) Addiction – Pipeline by Delpor Inc, 2022
- Table 37: Opium (Opioid) Addiction – Pipeline by DemeRx Inc, 2022
- Table 38: Opium (Opioid) Addiction – Pipeline by DMK Pharmaceuticals Inc, 2022
- Table 39: Opium (Opioid) Addiction – Pipeline by Elysium Therapeutics Inc, 2022
- Table 40: Opium (Opioid) Addiction – Pipeline by Emergent BioSolutions Inc, 2022
- Table 41: Opium (Opioid) Addiction – Pipeline by Ensysce Biosciences Inc, 2022
- Table 42: Opium (Opioid) Addiction – Pipeline by Eolas Therapeutics Inc, 2022
- Table 43: Opium (Opioid) Addiction – Pipeline by Epiodyne Inc, 2022
- Table 44: Opium (Opioid) Addiction – Pipeline by Ethismos Research Inc, 2022
- Table 45: Opium (Opioid) Addiction – Pipeline by Exxel Pharma Inc, 2022
- Table 46: Opium (Opioid) Addiction – Pipeline by Fab’entech SA, 2022
- Table 47: Opium (Opioid) Addiction – Pipeline by Fannin Partners LLC, 2022
- Table 48: Opium (Opioid) Addiction – Pipeline by Gilgamesh Pharmaceuticals Inc, 2022
- Table 49: Opium (Opioid) Addiction – Pipeline by Hunan Saiao Pharmaceutical Co Ltd, 2022
- Table 50: Opium (Opioid) Addiction – Pipeline by Indivior Plc, 2022
- Table 51: Opium (Opioid) Addiction – Pipeline by Inimmune Corp, 2022
- Table 52: Opium (Opioid) Addiction – Pipeline by Jazz Pharmaceuticals Plc, 2022
- Table 53: Opium (Opioid) Addiction – Pipeline by Kinoxis Therapeutics Pty Ltd, 2022
- Table 54: Opium (Opioid) Addiction – Pipeline by Lyndra Therapeutics Inc., 2022
- Table 55: Opium (Opioid) Addiction – Pipeline by Mayne Pharma Group Ltd, 2022
- Table 56: Opium (Opioid) Addiction – Pipeline by Mebias Discovery LLC, 2022
- Table 57: Opium (Opioid) Addiction – Pipeline by Mind Medicine MindMed Inc, 2022
- Table 58: Opium (Opioid) Addiction – Pipeline by Nirsum Laboratories Inc, 2022
- Table 59: Opium (Opioid) Addiction – Pipeline by Omeros Corp, 2022
- Table 60: Opium (Opioid) Addiction – Pipeline by Opiant Pharmaceuticals Inc, 2022
- Table 61: Opium (Opioid) Addiction – Pipeline by Orexo AB, 2022
- Table 62: Opium (Opioid) Addiction – Pipeline by Orphomed Inc, 2022
- Table 63: Opium (Opioid) Addiction – Pipeline by Osmotica Pharmaceutical Corp, 2022
- Table 64: Opium (Opioid) Addiction – Pipeline by OYE Therapeutics Inc, 2022
- Table 65: Opium (Opioid) Addiction – Pipeline by Palisades Therapeutics, 2022
- Table 66: Opium (Opioid) Addiction – Pipeline by Phoenix PharmaLabs Inc, 2022
- Table 67: Opium (Opioid) Addiction – Pipeline by Plumb Pharmaceuticals LLC, 2022
- Table 68: Opium (Opioid) Addiction – Pipeline by Revive Therapeutics Ltd, 2022
- Table 69: Opium (Opioid) Addiction – Pipeline by SafeRX Pharmaceuticals Inc, 2022
- Table 70: Opium (Opioid) Addiction – Pipeline by Sen-Jam Pharmaceutical LLC, 2022
- Table 71: Opium (Opioid) Addiction – Pipeline by Senzer Ltd, 2022
- Table 72: Opium (Opioid) Addiction – Pipeline by Serina Therapeutics Inc, 2022
- Table 73: Opium (Opioid) Addiction – Pipeline by Sparian Biosciences Inc, 2022
- Table 74: Opium (Opioid) Addiction – Pipeline by Syntropharma Ltd, 2022
- Table 75: Opium (Opioid) Addiction – Pipeline by Titan Pharmaceuticals Inc, 2022
- Table 76: Opium (Opioid) Addiction – Pipeline by VDM Biochemicals Inc, 2022
- Table 77: Opium (Opioid) Addiction – Pipeline by Vivreon Biosciences LLC, 2022
- Table 78: Opium (Opioid) Addiction – Pipeline by Yichang Humanwell Pharmaceutical Co Ltd, 2022
- Table 79: Opium (Opioid) Addiction – Pipeline by Zynerba Pharmaceuticals Inc, 2022
- Table 80: Opium (Opioid) Addiction – Dormant Projects, 2022
- Table 81: Opium (Opioid) Addiction – Dormant Projects, 2022 (Contd..1)
- Table 82: Opium (Opioid) Addiction – Discontinued Products, 2022
- List of Figures
- Figure 1: Number of Products under Development for Opium (Opioid) Addiction, 2022
- Figure 2: Number of Products under Development by Companies, 2022
- Figure 3: Number of Products under Development by Universities/Institutes, 2022
- Figure 4: Number of Products by Top 10 Targets, 2022
- Figure 5: Number of Products by Stage and Top 10 Targets, 2022
- Figure 6: Number of Products by Top 10 Mechanism of Actions, 2022
- Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Figure 8: Number of Products by Top 10 Routes of Administration, 2022
- Figure 9: Number of Products by Stage and Top 10 Routes of Administration, 2022
- Figure 10: Number of Products by Molecule Types, 2022
- Figure 11: Number of Products by Stage and Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.